Quantrx Biomedical (QTXB) 0.0070 $QTXB QuantRx
Post# of 273318
Posted On: 09/20/2016 9:01:07 PM
Quantrx Biomedical (QTXB) 0.0070 $QTXB
QuantRx Biomedical enters into Letter of Intent to acquire Global Cancer Diagnostics for undisclosed value
M2 - Wed Sep 30, 6:04AM CDT
QuantRx Biomedical (OTCBB:QTXB) revealed on Tuesday the launch of a letter of intent to acquire and merge with the CLIA-certified diagnostics laboratory Global Cancer Diagnostics to market a multitude of its non-invasive diagnostic tests, including The Lung Cancer Test, for an undisclosed value.
QuantRx Biomedical Signs Letter of Intent to Acquire Global Cancer Diagnostics
BusinessWire - Tue Sep 29, 6:30AM CDT
QuantRx(R) Biomedical Corporation ("QuantRx" or the "Company"
(OTCBB: QTXB) and Global Cancer Diagnostics Inc. ("Global", a privately held laboratory, jointly announce that they have signed a letter of intent to combine. Global, a CLIA-certified diagnostics laboratory based in Tempe, Arizona, has developed a low cost, highly accurate over-the-counter lung cancer screening test marketed under the name "The Lung Cancer Test(TM)". Global's proprietary technology combines low reagent and labor costs to provide an affordable self-pay solution. "The Lung Cancer Test(TM)" serves as a screening tool providing risk assessment, and is being sold as a laboratory developed test. Global's management brings deep industry knowledge and expertise in the areas of medical laboratory operations and CLIA laboratory licensing, as well as the marketing of blood tests.
QuantRx(R) Biomedical Provides Update on Technological Progress of Its Genomic Diagnostics Platforms
Marketwired - Tue Mar 03, 7:00AM CST
QuantRx(R) Biomedical Corporation ("QuantRx" or the "Company" (OTCBB: QTXB), an emerging provider of innovative healthcare solutions for feminine care, laboratory based point-of-care diagnostics, and genomic testing, all of which leverage its robust portfolio of patented intellectual property, is pleased to announce continued progress and exciting development across its business lines.
QuantRx Biomedical enters into Letter of Intent to acquire Global Cancer Diagnostics for undisclosed value
M2 - Wed Sep 30, 6:04AM CDT
QuantRx Biomedical (OTCBB:QTXB) revealed on Tuesday the launch of a letter of intent to acquire and merge with the CLIA-certified diagnostics laboratory Global Cancer Diagnostics to market a multitude of its non-invasive diagnostic tests, including The Lung Cancer Test, for an undisclosed value.
QuantRx Biomedical Signs Letter of Intent to Acquire Global Cancer Diagnostics
BusinessWire - Tue Sep 29, 6:30AM CDT
QuantRx(R) Biomedical Corporation ("QuantRx" or the "Company"
(OTCBB: QTXB) and Global Cancer Diagnostics Inc. ("Global", a privately held laboratory, jointly announce that they have signed a letter of intent to combine. Global, a CLIA-certified diagnostics laboratory based in Tempe, Arizona, has developed a low cost, highly accurate over-the-counter lung cancer screening test marketed under the name "The Lung Cancer Test(TM)". Global's proprietary technology combines low reagent and labor costs to provide an affordable self-pay solution. "The Lung Cancer Test(TM)" serves as a screening tool providing risk assessment, and is being sold as a laboratory developed test. Global's management brings deep industry knowledge and expertise in the areas of medical laboratory operations and CLIA laboratory licensing, as well as the marketing of blood tests. QuantRx(R) Biomedical Provides Update on Technological Progress of Its Genomic Diagnostics Platforms
Marketwired - Tue Mar 03, 7:00AM CST
QuantRx(R) Biomedical Corporation ("QuantRx" or the "Company"
(OTCBB: QTXB), an emerging provider of innovative healthcare solutions for feminine care, laboratory based point-of-care diagnostics, and genomic testing, all of which leverage its robust portfolio of patented intellectual property, is pleased to announce continued progress and exciting development across its business lines. 
(0)
(0)